3 Generic Drug Stocks to Watch as New Growth Drivers Emerge

Sandoz, Teva and Viatris target biosimilars, complex generics and specialty drugs as new growth drivers reshape the Medical - Generic Drugs industry.

Zacks Investment Research • Jun 5, 2026

Here's Why Viatris (VTRS) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jun 4, 2026

FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy

VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.

Zacks Investment Research • May 19, 2026

U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain

FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026.

PRNewsWire • May 18, 2026

Here's Why Viatris (VTRS) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 18, 2026

Why Viatris (VTRS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 13, 2026

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

Why Viatris (VTRS) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 12, 2026

Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)

Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consensus, with $450–550 million annual new product contributions and upside from branded assets. Key assets such as Selatogrel and Cenerimod, alongside upcoming launches (e.g., meloxicam), support reacceleration in growth and margin expansion.

Seeking Alpha • May 12, 2026

Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating

Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now.

Seeking Alpha • May 11, 2026